A Randomized, Double-blind, Placebo-controlled Phase I/IIa Clinical Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of MDR-001 Tablets Administrated Orally in Healthy Participants and Obese/ Overweight Participants
Latest Information Update: 11 Mar 2025
At a glance
- Drugs MDR-001 (Primary)
- Indications Obesity
- Focus Adverse reactions; First in man
- Sponsors MindRank
Most Recent Events
- 14 Jun 2023 Status changed from planning to recruiting, according to a MindRank media release.
- 14 Jun 2023 According to a MindRank media release, company announced that the first healthy volunteer is dosed.
- 28 Dec 2022 New trial record